Liquidia Technologies Inc (LQDA) - Net Assets

Latest as of June 2026: $195.11 Million USD

Based on the latest financial reports, Liquidia Technologies Inc (LQDA) has net assets worth $195.11 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($521.92 Million) and total liabilities ($326.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of Liquidia Technologies Inc to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets $195.11 Million
% of Total Assets 37.38%
Annual Growth Rate N/A
5-Year Change -31.44%
10-Year Change N/A
Growth Volatility 56.68

Liquidia Technologies Inc - Net Assets Trend (2016–2025)

This chart illustrates how Liquidia Technologies Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Liquidia Technologies Inc market cap and net worth.

Annual Net Assets for Liquidia Technologies Inc (2016–2025)

The table below shows the annual net assets of Liquidia Technologies Inc from 2016 to 2025. Also explore LQDA net assets growth trend to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2025-12-31 $44.75 Million -42.09%
2024-12-31 $77.28 Million +63.40%
2023-12-31 $47.29 Million -47.70%
2022-12-31 $90.42 Million +38.55%
2021-12-31 $65.27 Million -8.19%
2020-12-31 $71.09 Million +103.41%
2019-12-31 $34.95 Million +87.01%
2018-12-31 $18.69 Million +155.47%
2017-12-31 $-33.69 Million -84.66%
2016-12-31 $-18.25 Million --

Equity Component Analysis

This analysis shows how different components contribute to Liquidia Technologies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 54205392900.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock $87.00K 0.19%
Other Components $670.97 Million 1499.45%
Total Equity $44.75 Million 100.00%

Liquidia Technologies Inc Competitors by Market Cap

The table below lists competitors of Liquidia Technologies Inc ranked by their market capitalization.

Company Market Cap
The Swatch Group AG
F:UHRA
$5.89 Billion
Maxscend Microelectronics Co Ltd
SHE:300782
$5.89 Billion
Glacier Bancorp Inc
NYSE:GBCI
$5.89 Billion
Taiwan Business Bank
TW:2834
$5.90 Billion
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
$5.87 Billion
China Coal Energy Company Limited
F:CVV
$5.87 Billion
Fortnox AB
ST:FNOX
$5.87 Billion
Landstar System Inc
NASDAQ:LSTR
$5.86 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Liquidia Technologies Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 77,275,000 to 44,748,000, a change of -32,527,000 (-42.1%).
  • Net loss of 68,924,000 reduced equity.
  • Other factors increased equity by 36,397,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-68.92 Million -154.03%
Other Changes $36.40 Million +81.34%
Total Change $- -42.09%

Book Value vs Market Value Analysis

This analysis compares Liquidia Technologies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 126.39x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 $-3.59 $65.72 x
2017-12-31 $-3.92 $65.72 x
2018-12-31 $2.61 $65.72 x
2019-12-31 $1.89 $65.72 x
2020-12-31 $2.10 $65.72 x
2021-12-31 $1.31 $65.72 x
2022-12-31 $1.48 $65.72 x
2023-12-31 $0.73 $65.72 x
2024-12-31 $0.98 $65.72 x
2025-12-31 $0.52 $65.72 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Liquidia Technologies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -154.03%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -43.53%
  • • Asset Turnover: 0.48x
  • • Equity Multiplier: 7.33x
  • Recent ROE (-154.03%) is below the historical average (-109.17%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 0.00% -120.56% 1.56x 0.00x $-14.11 Million
2017 0.00% -401.68% 0.49x 0.00x $-25.79 Million
2018 -284.34% -1962.92% 0.05x 2.64x $-55.00 Million
2019 -136.16% -589.48% 0.12x 1.97x $-51.08 Million
2020 -84.07% -8080.11% 0.01x 1.40x $-66.87 Million
2021 -52.98% -269.03% 0.14x 1.44x $-41.11 Million
2022 -45.36% -257.39% 0.12x 1.43x $-50.06 Million
2023 -165.99% -448.89% 0.15x 2.50x $-83.23 Million
2024 -168.74% -931.65% 0.06x 2.98x $-138.12 Million
2025 -154.03% -43.53% 0.48x 7.33x $-73.40 Million

Industry Comparison

This section compares Liquidia Technologies Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $290,420,616
  • Average return on equity (ROE) among peers: -51.17%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Liquidia Technologies Inc (LQDA) $195.11 Million 0.00% 1.67x $5.88 Billion
Aurora Cannabis Inc (ACB) $1.08 Million -29.24% 0.07x $236.15 Million
ADC Therapeutics SA (ADCT) $140.89 Million 0.00% 0.10x $138.64 Million
Akanda Corp (AKAN) $-3.83 Million 0.00% 0.00x $1.51 Million
Akebia Ther (AKBA) $-30.58 Million 0.00% 0.00x $241.89 Million
Alkermes Plc (ALKS) $1.11 Billion -4.33% 0.82x $7.72 Billion
Amylyx Pharmaceuticals Inc (AMLX) $433.43 Million 11.37% 0.19x $3.58 Billion
Amphastar P (AMPH) $329.25 Million 3.20% 0.30x $980.07 Million
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) $896.36 Million -18.93% 3.86x $5.80 Billion
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) $20.01 Million -419.73% 172.53x $3.57 Billion
Anika Therapeutics Inc (ANIK) $5.00 Million -54.00% 0.38x $279.44 Million

About Liquidia Technologies Inc

NASDAQ:LQDA USA Drug Manufacturers - Specialty & Generic
Market Cap
$5.88 Billion
Market Cap Rank
#3209 Global
#1135 in USA
Share Price
$65.72
Change (1 day)
+0.64%
52-Week Range
$21.80 - $91.03
All Time High
$91.03
About

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung diseas… Read more